Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (611) Arrow Down
Filter Results: (611) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,026)
    • People  (4)
    • News  (257)
    • Research  (611)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (398)

Show Results For

  • All HBS Web  (1,026)
    • People  (4)
    • News  (257)
    • Research  (611)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (398)
← Page 4 of 611 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • June 2001
  • Supplement

Merck & Company: Evaluating a Drug Licensing Opportunity

By: Richard S. Ruback
Spreadsheet to (9-201-023). Download only. View Details
Citation
Purchase
Related
Ruback, Richard S. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Spreadsheet Supplement 201-707, June 2001.
  • 1996
  • Chapter

Eli Lilly and Company: Drug Development Strategy

By: S. Thomke, A. Nimgade and P. Pospisil
Keywords: Product Development; Corporate Strategy; Pharmaceutical Industry
Citation
Related
Thomke, S., A. Nimgade, and P. Pospisil. "Eli Lilly and Company: Drug Development Strategy." In Strategic Management of Technology and Innovation. 2nd ed. by R. Burgelman, M. A. Maidique, and S. C. Wheelwright. Burr Ridge, IL: Irwin/McGraw-Hill, 1996.
  • February 14, 2019
  • Other Article

We Should Treat Algorithms like Prescription Drugs

By: Andy Coravos, Irene Chen, Ankit Gordhandas and Ariel Dora Stern
Citation
Read Now
Related
Coravos, Andy, Irene Chen, Ankit Gordhandas, and Ariel Dora Stern. "We Should Treat Algorithms like Prescription Drugs." Quartz (February 14, 2019).
  • July – August 2000
  • Article

Drug Industry Mergers Won't Necessarily Benefit R&D

By: Rebecca M. Henderson
Keywords: Mergers and Acquisitions; Health; Research and Development
Citation
Find at Harvard
Read Now
Related
Henderson, Rebecca M. "Drug Industry Mergers Won't Necessarily Benefit R&D." Research-Technology Management 43, no. 4 (July–August 2000): 10–11.
  • June 2005
  • Article

A Rising Drug Industry: Pharmaceuticals since 1870

By: Arthur A. Daemmrich
Keywords: Health; Business History; Pharmaceutical Industry
Citation
Find at Harvard
Related
Daemmrich, Arthur A. "A Rising Drug Industry: Pharmaceuticals since 1870." Chemical and Engineering News (June 2005), 28–42.
  • October 2000 (Revised March 2003)
  • Case

Merck & Company: Evaluating a Drug Licensing Opportunity

By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
  • October 2024
  • Article

Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates

By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini
Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details
Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; United States
Citation
Find at Harvard
Purchase
Related
Kakani, Pragya, Michael Anne Kyle, Amitabh Chandra, and Luca Maini. "Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates." Health Affairs 43, no. 10 (October 2024): 1420–1427.
  • 28 Mar 2023
  • Research & Ideas

The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

Early in the COVID-19 pandemic, the US Food and Drug Administration faced the task of convincing a skeptical public of the safety of new vaccines when the agency began authorizing them for emergency use less than a year after the pandemic... View Details
Keywords: by Kasandra Brabaw; Pharmaceutical
  • 09 Feb 2024
  • HBS Case

Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive

what may at first blush appear to be an easier fix: new drugs such as Ozempic, Wegovy, and Mounjaro, says Harvard Business School Professor Regina E. Herzlinger, who has studied the American health care system for decades. Wegovy has been... View Details
Keywords: by Lane Lambert; Health; Pharmaceutical
  • August 2012 (Revised August 2024)
  • Case

ABC Pharmaceuticals

By: Regina E. Herzlinger and Erik R. Sparks
This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details
Keywords: Drug Development; Price; Product; Product Launch; Health Industry; Technology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Herzlinger, Regina E., and Erik R. Sparks. "ABC Pharmaceuticals." Harvard Business School Case 313-041, August 2012. (Revised August 2024.)
  • December 19, 2018
  • Article

It's Time to Reform the Orphan Drug Act

By: Nicholas Bagley, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
Citation
Find at Harvard
Read Now
Purchase
Related
Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "It's Time to Reform the Orphan Drug Act." NEJM Catalyst (December 19, 2018).
  • December 2009 (Revised April 2010)
  • Teaching Note

GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)

By: Robert S. Huckman
Teaching Note for [605074] and [605075]. View Details
Keywords: Restructuring; Health; Pharmaceutical Industry
Citation
Purchase
Related
Huckman, Robert S. "GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)." Harvard Business School Teaching Note 610-044, December 2009. (Revised April 2010.)
  • 2000
  • Chapter

Measuring Competence? Exploring Firm Effects in Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn
Keywords: Competency and Skills; Measurement and Metrics; Research and Development; Innovation and Invention; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Henderson, Rebecca M., and Iain Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Chap. 6 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter. New York: Oxford University Press, 2000.
  • December 1997 (Revised September 2002)
  • Supplement

Eli Lilly and Company: Drug Development Strategy (B)

By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Citation
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Eli Lilly and Company: Drug Development Strategy (B)." Harvard Business School Supplement 698-026, December 1997. (Revised September 2002.)
  • October 1987 (Revised March 1992)
  • Supplement

Boston Fights Drugs (B): Converting Research to Action

By: V. Kasturi Rangan and Jennifer Lawrence
Describes the results of the advertising pre-test described in the (A) case. The group must now decide how to implement its findings for maximum impact. View Details
Keywords: Advertising; Welfare; Strategy; Advertising Industry; Boston
Citation
Purchase
Related
Rangan, V. Kasturi, and Jennifer Lawrence. "Boston Fights Drugs (B): Converting Research to Action." Harvard Business School Supplement 588-032, October 1987. (Revised March 1992.)
  • 08 Mar 2018
  • Cold Call Podcast

Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?

Keywords: Health
  • June 1992
  • Teaching Note

Novel Combination of Two Drugs (B) and (C) and Technology Transfer Anti-Inflammatory Drug (B) and (C), Teaching Note

By: Regina E. Herzlinger
Keywords: Innovation and Invention; Technology; Pharmaceutical Industry
Citation
Related
Herzlinger, Regina E. "Novel Combination of Two Drugs (B) and (C) and Technology Transfer Anti-Inflammatory Drug (B) and (C), Teaching Note." Harvard Business School Teaching Note 192-124, June 1992.
  • Article

Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users

By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Citation
Find at Harvard
Read Now
Purchase
Related
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
  • March 2007
  • Teaching Note

Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)

By: Felix Oberholzer-Gee
Teaching note to 706454. View Details
Citation
Purchase
Related
Oberholzer-Gee, Felix. "Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)." Harvard Business School Teaching Note 707-542, March 2007.
  • 2004
  • Book

Pharmacopolitics: Drug Regulation in the United States and Germany

By: Arthur A. Daemmrich
Keywords: Health; Governing Rules, Regulations, and Reforms; Government and Politics; United States; Germany
Citation
Find at Harvard
Read Now
Related
Daemmrich, Arthur A. Pharmacopolitics: Drug Regulation in the United States and Germany. University of North Carolina Press, 2004. (Winner of Edward Kremers Award of the American Institute of the History of Pharmacy For best book in pharmaco-historical writing published in the previous two years presented by American Institute of the History of Pharmacy.)
  • ←
  • 4
  • 5
  • …
  • 30
  • 31
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.